INTRODUCTION
Of the three equine herpesviruses identified, type 1 (EHV-I) has been most extensively studied because of the severity of the disease it causes. The prominent clinical symptoms of EHV-1 infection include respiratory disease, abortion, perinatal foal disease and myeloencephalitis (Campbell & Studdert, 1983) . Disease was initially thought to be due to infection with one virus type but DNA restriction endonuclease analysis (Studdert, 1983) and specific monoclonal antibodies (Yeargan et al., 1985) have been used to differentiate the virus into abortifacient and respiratory isolates. These were classified as subtypes 1 and 2 of EHV-1. However, due to differences observed at the DNA level these viruses are now often referred to as separate types (type 1 and type 4) (Studdert & Kamada, 1983) .
Although vaccines are available they do not provide an adequate spectrum or duration of protection, and require repeated administration (Doll, 1961 ; Bryans, 1976; Burrows et al., 1984) . Great interest is being shown in the development of an improved vaccine (Anonymous, 1988) . In this regard a definition of the immune effector mechanisms induced by vaccination (Stokes & Wardley, 1988) and the identification of protective viral glycoproteins are important.
Furthermore, as a practical device for the development of improved vaccines, there can be little doubt that a suitable small animal model would be of immense benefit. Previously, Anderson & Goodpasture (1942) were successful in infecting the Syrian hamster with EHV-1 and some aspects of immunity were subsequently investigated by W ilks & Coggins (1977) who demonstrated passive protection from infection on transfer of immune splenocytes, antiserum 0000-8726 © 1989 SGM A. STOKES AND OTHERS or immune peritoneal exudate cells. Protection could also be induced in hamsters by immunization with a glycoprotein-containing fraction of the viral envelope (Papp-Vid & Derbyshire, 1978) . The serious limitation of this model however is that an acute disease is produced with hamsters dying in 3 to 5 days. This is most unlike the equine disease and it does not permit full assessment of immune effector mechanisms.
Besides being components of the intact virus, herpesvirus glycoproteins may also be expressed on the membranes of infected cells (Jennings et al., 1987) and are targets for cellular and humoral immune responses (Blacklaws et aL, 1987; Friedman et al., 1984; Sullivan & Smith, 1987) . Their importance in immunity has been demonstrated in mice which were passively protected by monoclonal antibodies to various herpes simplex virus type 1 (HSV-1) glycoproteins (Balachandran et al., 1982; Kumel et al., 1985) . EHV-1 has at least 11 glycoproteins (gp) exposed on the surface of the viral envelope (Turtinen & Allen, 1982) . The regions of the genome that code for six of these, i.e. gp 2, 10, 13, 14, 17/18 and 21/22a were mapped by the use of monoclonal antibodies and the expression vector 2gtl 1 (Allen & Yeargan, 1987) . Furthermore, gpl4, gpl3 and gpl7/18 mapped to positions collinear with HSV glycoproteins B, C and E respectively (Allen & Yeargan, 1987; Allen & Coogle, 1988) .
The studies reported in this paper were undertaken to develop a better model of EHV-1 infection and to assess both the cell-mediated and humoral immune responses in this model. In addition, the protective effect of anti-EHV-1 monoclonal antibodies to the glycoproteins was assessed in an effort to define viral epitopes of potential importance in immunization against this infection.
METHODS
Experimental animals. Six-to 8-week-old female golden Syrian hamsters (Mesocricetus auratus) of the DSN inbred strain were used and these were obtained from Shamrock Farms, Animals were housed in RM2 cages supplied by NKC.
Viruses. The prototype strain of the EHV-1 group, Kentucky D (KyD) (Doll & Wallace, 1954) , was used and this had been passaged 300 times through hamsters and in tissue culture thereafter (Burrows, 1968) . Virus was purified by potassium tartrate gradient centrifugation (Lopez & O'Reilly, 1977) , HSV-1 was used as a control. Hamsters were challenged either intraperitoneally (i.p.) or intranasally (i.n.) with 1 × 106TCIDsounits(100~tl)ofpurified virus.
Bleeding of animals and passive transfer of immune sera or monoclonal antibodies. Hamsters were bled by cardiac puncture following ether anaesthesia and approximately 0-5 ml of blood was removed from each animal. The blood was allowed to clot and the serum was collected. Heat-inactivated serum (200 ~tl) which had a neutralizing antibody titre of 1 / 128 was passively transferred by intracardiac inoculation either 24 h before virus challenge with 1 × 106 TCIDso units EHV-1 (animals killed 48 h after challenge) or after virus challenge (alaimals killed at 48 h after transfer of antibody). In the same manner 100 ~tl of 1/2 dilution of monoclonal antibody to the major glycoproteins of EHV-I (Allen & Yeargan, 1987) were administered to groups of four or five hamsters. Animals were challenged either i.n. or i.p. with 1 x 106 TCIDs0 units of EHV-1 1 h later, and then killed at 48 h postinfection (p.i.) and tissues were examined for infectious virus.
Procedure for virus isolation. A 10~ (w/v) suspension of tissue in Eagle's medium [2~ foetal calf serum (FCS), 100 international units/ml penicillin and 100 ~tg/ml streptomycin (cMEM)] was prepared by grinding with a mortar and pestle. Tenfold dilutions of the supernatant (0,1 ml) were added to confluent monolayers of BHK-21 cells (Whalley et al., 1981) . Following a 2 h adsorption period at 37 °C, cells were washed with phosphate-buffered saline (PBS) and re-fed with cMEM (1 ml), after which time tubes were put into a roller and cells were examined daily for the presence of a characteristic cytopathic effect.
Virus was identified by neutralization of approximately 100 TCID50 units (100 p,1) of virus with a 1/10 dilution of hyperimmune serum at 37 °C for 2 h. A 200 lal sample was removed and inoculated in triplicate onto confluent monolayers of BHK-21 cells. Cells were examined after 4 days to detect virus neutralization.
Cytotoxicity assays
Effector cells. Animals were killed and their spleens placed in medium (RPMI supplemented with 5% heat inactivated FCS and 25 mM-HEPES). Single-cell suspensions were prepared by teasing the spleens apart using forceps. Erythrocytes were removed either by lysis with 0-83 ~ NH4CI (Lawman et aL, 1980) or by Ficoll-Hypaque separation. Cells were washed three times in RPMI (5% heat-inactivated FCS) and their concentration was adjusted to 5 x 106 cells/ml.
Preparation of target cells. Hamster embryo fibroblasts, prepared according to the method of Freshney (1983) Complement-mediated antibody lysis. BHK-21 cells prepared as above were infected with EHV-1 and used at a concentration of 1 × 105/ml. Cells (100 ~tl), heat-inactivated test serum and a 1/8 dilution of low toxicity guineapig complement (Cedarlane) were added to a 96-weU microtitre plate (Nunc) followed by incubation for 3 h. Fifty per cent of the contents of each well was removed and the results were calculated as above. , 1985) . Splenocytes were treated with a 1/150 dilution of the monoclonal antibody for 1 h at 37 °C, followed by centrifugation and resuspension in low toxicity guinea-pig complement (Cedarlane) diluted 1/8 in PBS. Cells plus complement were incubated for a further 30 rain, after which time the percentage viability was assessed using the trypan blue dye exclusion technique and viable cells were used in cytotoxicity assays. 
Lysis ofeffector cells by monoclonal antibody and complement.

Fluorescence-activated cellsorter (FACS) analysis.
Solid phase ELISA for the detection of anti-EHV-1 (KyD) antibodies.
Microtitre plates (Nunc) were coated overnight with a purified virus preparation in carbonate/bicarbonate buffer. Plates were washed with PBS containing 1% Tween 20 (PBST) and test serum diluted 1/400 in PBST was added. The plates were incubated for 1 h and washed. A rabbit anti-hamster IgG (Nordic) diluted 1/3200 in PBST was then added and the plate incubated as before. After washing, a swine anti-rabbit horseradish peroxidase conjugate (Dako) diluted 1/1000 was added and the plate was again incubated at 37 °C for 1 h. The plate was washed and the enzyme substrate o-phenylene diamine added. After 10 min the reaction was stopped using 100 ktl 2 M-H2SO 4. Absorbance was read at 492 nm.
The subclass of the monoclonal antibodies used in these experiments was assessed by an ELISA and by an immunodiffusion technique. Purified antigen was absorbed to the solid phase of a microtitre plate and dilutions of the monoclonal antibody were allowed to react with this. Sheep anti-mouse subclass antibodies (The Binding Site, University of Birmingham) were used to detect bound antibody. Sheep immunoglobulins were detected using an anti-sheep immunoglobulin horseradish peroxidase conjugate. Immunodiffusion was carried out using agarosecoated plates and anti-mouse subclass monoclonal antibodies (The Binding Site).
Fluorescent antibody technique for the detection of EHV-1 antigens in infected cells. Hamster embryo fibroblasts
were infected at an m.o.i, of 0-5 and incubated overnight. Cells were fixed in acetone and a 1/10 dilution of an anti EHV-1 (KyD) hyperimmune guinea-pig serum was added. The cells were incubated for 30 min in a moist chamber at 37 °C followed by washing three times in PBS. An anti-guinea-pig FITC conjugate (Dako) was diluted 1/10 and added to the slide which was incubated again for 30 min at 37 °C. The slide was washed as before, mounted in glycerol (5% PBS) and then examined using a fluorescence microscope (Leitz).
RESULTS
Isolation of virus from hamsters challenged with EHV-I (KyD)
It was possible to infect the DSN inbred hamster either i.p. or i.n. with 1 x 106 TCIDs0 units of a subtype 1 (KyD) strain of EHV-1 (Table 1) . By day 2 virus was isolated from the livers of all animals in both groups and from the lungs of one i.n. infected hamster. Virus was consistently isolated from liver, lung, heart, kidney and spleen of i.p. infected hamsters on day 4 but not thereafter and although i.n. exposure resulted in infection, this was less consistent, isolations being sporadic over the 4 days following inoculation. In one animal virus was isolated from the liver, lung and spleen and in a second the liver. The majority of virus isolations were consistently made from the liver. Infection resulted in the occasional death but more often animals were clinically affected for 4 days and then recovered. The livers of infected animals were lighter in colour than those of the controls. Virus clearance was apparent by day 6.
Cell-mediated immune response to EHVol
Cell-mediated immunity to EHV-1 was assessed by measuring lysis of cells infected with homologous virus by splenocytes from primed animals or mock-infected autologous target cells (DSN hamster embryo fibroblasts). At an effector to target cell ratio of 100 : 1 these cells showed a virus-specific lytic ability by day 6 which peaked by day 12 and dropped precipitously thereafter (Fig. 1) .
Virus specificity of the cytotoxic cell
Splenocytes from EHV-l-infected hamsters were also able to lyse heterologous target cells (BHK-21 cells) infected with homologous virus. The virus specificity of the response was assessed using BHK-21 target cells infected with HSV-1, EHV-1 (KyD) or mock-infected and incubating with splenocytes from animals primed 8 days previously (Table 2) . Lysis of EHV-1-infected target cells by splenocytes from two primed animals was quite high at effector :target ratios of 100:1 (34~ and 23~) declining as ratios were reduced. 0 ~. Low levels of lysis were observed using splenocytes from the unprimed animal with either HSV-1, EHV-1 mock-infected target cells (7 to 8~) at an effector:target cell ratio of 100:1.
Identification of the effector cell
To characterize the cytotoxic cell type, a monoclonal antibody which lysed 57 ~o of inguinal lymph node cells and 27~ of splenocytes in the presence of complement and was specific for hamster peripheral T lymphocytes (antibody 20) was used (Witte et al., 1985) . The results of FACS analysis of the splenocytes bearing this marker showed two separate populations both of approximately the same cell size though the major population which contained 19.66~o of the positive cells showed a higher intensity of fluorescence when compared to the minor cell population which contained 4.91 ~ positive cells. Following treatment of effector cells with the monoclonal antibody plus complement (Table  3) , lysis of the virus-infected target cells fell from 31 ~o to 0H, indicating that the cytolysis was T cell-mediated. Splenocytes from non-infected animals showed a background lysis level of 5 ~. Treatment of primed splenocytes with a control monoclonal antibody reduced the lysis from 35?/oo to 30~o.
Humoral immunity to EHV-1 infection
The humoral response to EHV-1 infection was measured in two ways, by a virus-specific ELISA (Fig. 2) and by a complement-mediated antibody lysis assay (Fig. 3) . Antibodies detectable by ELISA were present between days 4 and 6 and levels showed a linear increase between days 4 and 10. A further increase occurred between days 16 and 30. Complementmediated antibody lysis had also started to develop by day 4 (Fig. 3) and increased sharply by day 6 (mean 2.28 log10 endpoint titre). A peak was reached by day 10 (mean 2-72) and levels fluctuated thereafter remaining high until day 88, the final point at which serum was assayed. 
Passive protection using immune serum
To examine the role of humoral immunity in controlling the replication of virus in tissues, passive protection experiments were carried out. When heat-inactivated serum with a neutralizing antibody titre of 1/128 was administered to animals before challenge (Table 4) virus titres in the liver were reduced significantly compared to the control group (P < 0.01), virus being isolated from the liver of one animal only at barely detectable levels and four of five animals were protected. On transfer of immune serum 24 h post-challenge the amount of virus in the liver was reduced compared to controls, i.e. titres of ~< 101"5 to 104.5 TCIDso/g of tissue as opposed to levels of ~< 101"5 to >1 108.5 TCID50/g in controls. The protective effect of serum was lost after dilution. It would appear from these results that the transfer of immune serum 24 h post-inoculation reduced the titres of virus recovered whereas transfer 24 h before challenge was highly protective.
Passive transfer of monoclonal antibodies to the six major glycoproteins of EHV-1 Comparable levels of immunity were obtained in animals challenged either i.n. or i.p. in protection tests (Table 5 ). Individual monoclonal antibodies to gp2, gp 10 and gp21/22a gave no protection in either group of animals. However, monoclonal antibodies to gp17/18 and gpl3 provided protection from challenge of 75% of i.n. infected hamsters and 80% of i.p. infected hamsters. Administration of all six monoclonal antibodies before virus challenge resulted in all animals being completely protected with the exception of one i.p. challenged hamster. Although monoclonal antibody to gp14 protected 100% of i.p. challenged animals only 20% of the i.n. challenged animals were protected. The pattern of virus isolation from the liver was consistent whereas isolations from the lungs varied even in the control animals which were challenged i.n.; administration of monoclonal antibody enhanced viral replication in the lungs in some instances.
DISCUSSION
This study has defined some of the virological and immunological events seen in the Syrian hamster after challenge with a non-lethal subtype 1 isolate of EHV-1 and has established, using protective monoclonal antibodies, specific viral glycoproteins of interest in vaccine development.
In a previous study of EHV-I in the hamster (Wilks & Coggins, 1977) , i.p. challenge with a virulent isolate of EHV-1 (strain KyB) resulted in 100% mortality by day 3 with peak levels of virus in the liver at between 48 and 60 h p.i. and in the lungs at 48 h p.i. Little opportunity exists with this acute model to investigate immunological mechanisms. However, this is the first report that by using the KyD strain of EHV-1 and DSN inbred hamsters a subacute model is possible. Animals infected by i.p. or i.n. administration of high titre EHV-1 (KyD) developed a selflimiting infection in which virus clearance was complete by day 6. Intraperitoneal inoculation of virus resulted in a systemic infection, virus being isolated from the major organs by day 4. This route of infection results in transport via the peritoneal macrophages to regional lymph nodes and dissemination from here to major organs (Wilks & Coggins, 1977) . Intranasal inoculation gave a more sporadic pattern of virus isolation. This route, however, has the advantage of following more closely the natural route of infection and has been used to administer other respiratory pathogens (Hjorth et al., 1988; King et al., 1987) .
By day 6 post-infection, the spleens of primed animals contained virus-specific primary cytotoxic T lymphocytes which lysed autologous cells (hamster embryo fibroblasts) which were major histocompatibility complex (MHC)-compatible and BHK-21 cells infected with EHV-1 but not HSV-1. Cytotoxic T lymphocytes have been implicated as the first specific lines of defence following infection by virus and have recently been demonstrated in EHV-1 (subtype 2) infection of the horse following expansion of the relevant population by in vitro culture (Bridges & Edington, 1987) . In the Syrian hamster two closely linked MHC class 1 (Hm-1) genes have been cloned (McGuire et al., 1986) and are probably analogous of the murine K and Qa region genes though they exhibit limited polymorphism (McGuire et al., 1985) as determined by biochemical and DNA (Atherton et al., 1984) criteria. This probably explains the lysis of both types of target cell. Two subsets of hamster T lymphocytes exist, cytotoxic T lymphocytes and inducer delayed type hypersensitivity cells (Witte et al., 1985) , analogous to the Lyt2 + and L3T4 phenotypes in the mouse. Monoclonal antibody 20, which detects the majority of peripheral T lymphocytes, in the presence of complement destroyed the cytotoxicity of sensitized spleen cells from infected hamsters, identifying these as being of the T cell lineage. This antibody does not recognize surface antigens on natural killer cells (SteinStreilein et al., 1985) .
Antibody appears to be important for protection in this model, as the appearance of virusspecific antibodies following infection correlated well with viral clearance. These antibodies were able to lyse virus-infected target cells in vitro in the presence of complement. If this occurred in vivo in cells where virus assembly was incomplete any further spread of infection would be halted. Complement-mediated antibody lysis of infected cells may be a more effective mechanism of virus clearance than neutralizing antibody as herpesviruses are able to spread from cell to cell by intercellular bridging even earlier than by the extraceUular route, and in so doing evade neutralizing antibodies (Babiuk et al., 1975) . Thus complement-mediated antibody lysis may be one mechanism for antibody-mediated immune protection, although opsonization merits investigation as another possibility. In the case of EHV-I infection of the horse such antibodies were apparent by day 10 p.i., the time at which virus is beginning to be cleared from infected animals (Stokes & Wardley, 1988) .
Furthermore, in passive protection experiments transfer of serum 24 h before challenge protected 80 ~ of animals and transfer of serum post-challenge reduced the titres of recoverable virus. Early experiments in the horse also showed a protective effect of immune serum (Dimock & Edwards, 1936 ) though this must be viewed with caution as infection has also been shown to occur in the presence of neutralizing antibodies (Burrows et al., 1984) .
Although EHV-1 has at least 11 glycoproteins situated in the viral envelope, their functions are unknown (Turtinen & Allen, 1982) . The availability of monoclonal antibodies to these virus components (Allen & Yeargan, 1987) however allowed us to investigate their potential as targets of immunity (Table 5) . Administration of a pool of monoclonal antibodies against the six major glycoproteins provided 100 ~ protection of i.n. challenged hamsters and 80 ~ of i.p. challenged hamsters. It is also interesting that monoclonal antibody to gpl3 (which maps genetically to a region collinear with gpC of other alpha herpesviruses) protected 75 ~ of i.n. challenged animals and 80~ of i.p. challenged animals. Monoclonal antibody to gpl4 (which maps to a region collinear with gpB of other alphaherpesviruses) protected 100 ~ of i.p. challenged animals but only 20~ of i.n. challenged hamsters. The gpB component of HSV-I is essential for virion infectivity (Little et al., 1981) and will induce delayed type hypersensitivity and antibody responses (Blacklaws et al., 1987) whereas gpC is an important receptor for the activated complement component C3b (Friedman et al., 1984) which enables the virus to evade the action of complement-mediated neutralization (McNearney et al., 1987) . The functions of EHV-I glycoproteins are however unknown. Therefore the exact mechanism by which these antibodies induced protection is unclear as they were unable to neutralize KyI) virus in vitro (neutralizing antibody titre < 1/20) and did not mediate antibody-dependent cell-mediated cytotoxicity (ADCC) of virus-infected target cells in the presence of murine peritoneal macrophages unless all six monoclonal antibodies were used together (unpublished result). Interestingly, the isotype of the protective monoclonal antibodies was IgG2a (Table 6 ), a subclass which is able to bind to murine macrophages and activate the classical pathway of complement (Spiegelberg, 1974) . Thus either an ADCC or complement-mediated antiviral mechanism may operate in vivo. In HSV-1 infection a suggested mechanism for protection was by ADCC or complement-mediated antibody lysis, as monoclonal antibodies were also unable to neutralize virus in vitro (Balachandran et al., 1982) . Although the protective mechanism against EHV-I is not yet resolved our results provide preliminary data on the efficiency of protecting hamsters from infection by EHV-I and the potential for specific glycoproteins to induce protective antibody responses.
